CapsoVision, Inc (NASDAQ:CV)
| Market Cap | 336.29M+27.9% |
| Revenue (ttm) | 13.89M+11.0% |
| Net Income | -29.83M-46.0% |
| EPS | -0.63-37.0% |
| Shares Out | 53.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 119,878 |
| Open | 6.22 |
| Previous Close | 6.20 |
| Day's Range | 6.17 - 6.44 |
| 52-Week Range | 4.50 - 15.37 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 9.00(+42.41%) |
| Earnings Date | Nov 12, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About CV
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Nov 12, 2026Earnings report
Ask Barron about CV
$CV stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in CV holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CV's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CV Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CV Revenue by Segment or Geography
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CV patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CV from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CV
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $5.98M |
| IWMiShares Russell 2000 ETF | $5.30M |
| VXFVanguard Extended Market ETF | $2.48M |
| IWOiShares Russell 2000 Growth ETF | $2.06M |
| VTWOVanguard Russell 2000 ETF | $1.31M |
| IWCiShares Micro-Cap ETF | $649.80K |
Estimated from each fund’s disclosed top holdings × AUM
CV Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CV’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
Healthcare: 53 sector peers carry a ranked score; this one has no qualifying buying in the window · sector average 67.1
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Sep 19Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.